These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
499 related articles for article (PubMed ID: 26994448)
1. CD4+CD25+ regulatory T cells in tumor immunity. Chen X; Du Y; Lin X; Qian Y; Zhou T; Huang Z Int Immunopharmacol; 2016 May; 34():244-249. PubMed ID: 26994448 [TBL] [Abstract][Full Text] [Related]
2. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956 [TBL] [Abstract][Full Text] [Related]
3. Human umbilical vein endothelial cells promote the inhibitory activation of CD4(+)CD25(+)Foxp3(+) regulatory T cells via PD-L1. Chen WJ; Hu XF; Yan M; Zhang WY; Mao XB; Shu YW Atherosclerosis; 2016 Jan; 244():108-12. PubMed ID: 26615520 [TBL] [Abstract][Full Text] [Related]
4. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115 [TBL] [Abstract][Full Text] [Related]
6. CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. Bianchini R; Bistoni O; Alunno A; Petrillo MG; Ronchetti S; Sportoletti P; Bocci EB; Nocentini G; Gerli R; Riccardi C Eur J Immunol; 2011 Aug; 41(8):2269-78. PubMed ID: 21557210 [TBL] [Abstract][Full Text] [Related]
7. PTD-hFOXP3 protein acts as an immune regulator to convert human CD4(+)CD25(-) T cells to regulatory T-like cells. Liu X; Xu X; Lin X; Tian Y; Ji B; Xia S; Xu S; Yin Q; Zhang M; Jiao Z; Wang S; Xu H; Shao Q J Cell Biochem; 2012 Dec; 113(12):3797-809. PubMed ID: 22806628 [TBL] [Abstract][Full Text] [Related]
8. Frequency and expression of inhibitory markers of CD4(+) CD25(+) FOXP3(+) regulatory T cells in patients with common variable immunodeficiency. Arandi N; Mirshafiey A; Abolhassani H; Jeddi-Tehrani M; Edalat R; Sadeghi B; Shaghaghi M; Aghamohammadi A Scand J Immunol; 2013 May; 77(5):405-12. PubMed ID: 23432692 [TBL] [Abstract][Full Text] [Related]
9. Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+Treg cells. Wang B; Li B; Dai Z; Ren S; Bai M; Wang Z; Li Z; Lin S; Wang Z; Huang N; Yang P; Liu M; Min W; Ma H Int J Biochem Cell Biol; 2014 Oct; 55():98-108. PubMed ID: 25168696 [TBL] [Abstract][Full Text] [Related]
10. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts. Yu Y; Huang R; Zong X; He X; Mo W BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040 [TBL] [Abstract][Full Text] [Related]
11. CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity. Chen X; Du Y; Huang Z Immunol Lett; 2012; 148(1):83-9. PubMed ID: 23000301 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo. Wu T; Zhang L; Xu K; Sun C; Lei T; Peng J; Liu G; Wang R; Zhao Y Transpl Immunol; 2012 Aug; 27(1):30-8. PubMed ID: 22613676 [TBL] [Abstract][Full Text] [Related]
13. Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells. Shuai X; Wei-min L; Tong YL; Dong N; Sheng ZY; Yao YM Sci Rep; 2015 Sep; 5():14478. PubMed ID: 26411375 [TBL] [Abstract][Full Text] [Related]
14. Impaired control of effector T cells by regulatory T cells: a clue to loss of oral tolerance and autoimmunity in celiac disease? Hmida NB; Ben Ahmed M; Moussa A; Rejeb MB; Said Y; Kourda N; Meresse B; Abdeladhim M; Louzir H; Cerf-Bensussan N Am J Gastroenterol; 2012 Apr; 107(4):604-11. PubMed ID: 22108452 [TBL] [Abstract][Full Text] [Related]
15. IL-1R1 is expressed on both Helios(+) and Helios(-) FoxP3(+) CD4(+) T cells in the rheumatic joint. Müller M; Herrath J; Malmström V Clin Exp Immunol; 2015 Oct; 182(1):90-100. PubMed ID: 26076982 [TBL] [Abstract][Full Text] [Related]
16. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells. Kakita N; Kanto T; Itose I; Kuroda S; Inoue M; Matsubara T; Higashitani K; Miyazaki M; Sakakibara M; Hiramatsu N; Takehara T; Kasahara A; Hayashi N Int J Cancer; 2012 Dec; 131(11):2573-83. PubMed ID: 22419479 [TBL] [Abstract][Full Text] [Related]
17. Roles of CD4+CD25(high) FOXP3+ Tregs in lymphomas and tumors are complex. Ke X; Wang J; Li L; Chen IH; Wang H; Yang XF Front Biosci; 2008 May; 13():3986-4001. PubMed ID: 18508492 [TBL] [Abstract][Full Text] [Related]
18. Significance of immunoregulatory T cells in different stages of breast cancer patients. Abo-Elenein A; Elgohary SE; Hashish A; El-Halaby E Egypt J Immunol; 2008; 15(2):145-52. PubMed ID: 20306697 [TBL] [Abstract][Full Text] [Related]
19. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Kessel A; Haj T; Peri R; Snir A; Melamed D; Sabo E; Toubi E Autoimmun Rev; 2012 Jul; 11(9):670-7. PubMed ID: 22155204 [TBL] [Abstract][Full Text] [Related]
20. The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. Zhang Y; Yao YM; Huang LF; Dong N; Yu Y; Sheng ZY J Interferon Cytokine Res; 2011 Feb; 31(2):249-57. PubMed ID: 21087077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]